Mirum Pharmaceuticals, Inc.

NasdaqGM:MIRM Stock Report

Market Cap: US$6.5b

Mirum Pharmaceuticals Management

Management criteria checks 3/4

Mirum Pharmaceuticals' CEO is Chris Peetz, appointed in Mar 2019, has a tenure of 7.5 years. total yearly compensation is $10.44M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 0.59% of the company’s shares, worth $38.43M. The average tenure of the management team and the board of directors is 4.7 years and 7.2 years respectively.

Key information

Chris Peetz

Chief executive officer

US$10.4m

Total compensation

CEO salary percentage7.23%
CEO tenure7.5yrs
CEO ownership0.6%
Management average tenure4.7yrs
Board average tenure7.2yrs

Recent management updates

Recent updates

Narrative Update • Sep 04

MIRM: 2026 PSC Decision Will Drive Bullish Repricing Potential

Analysts have trimmed their consolidated price target on Mirum Pharmaceuticals to about $138 from roughly $144, reflecting updated revenue growth and discount rate assumptions, along with higher modeled profit margins and a lower future P/E multiple. Analyst Commentary Recent Street research on Mirum Pharmaceuticals shows a mix of optimism about the commercial business and caution around the regulatory path for key pipeline assets.
Narrative Update • Aug 21

MIRM: PSC Regulatory Reset Will Reframe Long Term Earnings Outlook

Mirum Pharmaceuticals' analyst price targets have edged lower by single digits in recent weeks, with revisions such as $150 to $137, $146 to $137, $145 to $140, and $129 to $123, as analysts balance raised revenue guidance and a supportive base business against fresh regulatory uncertainty around the volixibat program in primary sclerosing cholangitis. Analyst Commentary Recent research on Mirum Pharmaceuticals points to a mixed but generally constructive tone, with bullish analysts stressing execution in the base business and pipeline potential, even as they factor in new regulatory questions around volixibat in primary sclerosing cholangitis.
Narrative Update • Aug 06

MIRM: Raised Guidance And PSC Pathway Shifts Will Drive Future Repricing

Mirum Pharmaceuticals' updated fair value estimate has eased from about $125.00 to roughly $118.11, reflecting recent analyst price target trims that cite strong core performance but added uncertainty around regulatory timing for volixibat in primary sclerosing cholangitis. Analyst Commentary Recent Street research on Mirum Pharmaceuticals shows a mix of confidence in the existing commercial portfolio and caution around execution risk, particularly tied to volixibat in primary sclerosing cholangitis.
Narrative Update • Jul 14

MIRM: Fair Outlook Weighs Rare Disease Progress Against Hepatitis Delta Execution Risk

Mirum Pharmaceuticals' fair value estimate has been raised from $115 to $125 as analysts cite higher price targets across the Street, supported by growing confidence in the company's rare disease portfolio and its potential role in the emerging hepatitis delta virus treatment market. Analyst Commentary Recent Street research on Mirum Pharmaceuticals points to a cluster of higher price targets, with several large firms citing the rare disease portfolio and exposure to hepatitis delta virus as key drivers of their work.
Seeking Alpha • Jul 04

Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio

Summary Mirum Pharmaceuticals is evolving into a leading liver disease franchise, with robust revenue growth and a diversified pipeline targeting high-value indications. MIRM raised its 2026 global sales guidance to $660–$680 million, supported by strong LIVMARLI performance. Recent acquisitions have delayed cash flow positivity to 2028, but the company’s pipeline—Volixibat, MRM-3379, and Brelovitug—offers multiple blockbuster opportunities. Despite near-term losses, consensus sees sharp EPS gains by 2028; upcoming clinical readouts and FDA decisions are key catalysts for the stock. Read the full article on Seeking Alpha
Narrative Update • Jun 30

MIRM: Fair Outlook Balances PSC Milestones With Hepatitis Delta Market Execution

Mirum Pharmaceuticals' fair value estimate has moved from $95.00 to $115.00 as analysts point to a series of higher price targets and growing confidence that the company's rare disease portfolio and potential hepatitis delta virus therapies can tap into what is seen as an underappreciated market opportunity. Analyst Commentary Recent Street research on Mirum Pharmaceuticals centers on how its rare disease portfolio and hepatitis delta virus opportunity are reflected in current valuation.
Narrative Update • Jun 16

MIRM: 2026 PSC And HDV Readouts Will Recast Long Term Earnings Outlook

Analysts have inched their blended fair value estimate for Mirum Pharmaceuticals slightly lower to about $176.64 per share, while recent price target increases toward the $140 to $150 range reflect growing confidence in the company’s rare disease portfolio and its potential role in the expanding hepatitis delta virus treatment market. Analyst Commentary Recent research on Mirum Pharmaceuticals highlights a generally constructive tone, with several bullish analysts pointing to the company’s rare disease portfolio and hepatitis delta virus exposure as key factors supporting higher valuation ranges.
Narrative Update • Jun 01

MIRM: 2026 PSC And HDV Readouts Will Drive Bullish Repricing

The analyst price target for Mirum Pharmaceuticals has been raised from $129.73 to $144.15. Analysts attribute this change to updated expectations for revenue growth, profit margins, and future P/E, supported by recent research that highlights potential contributions from Livmarli label expansion and the Volixibat pipeline.
Narrative Update • May 18

MIRM: 2026 PSC Readout Will Reshape Long Term Earnings Outlook

Analysts have raised their average price target for Mirum Pharmaceuticals from about $140 to roughly $177, citing updated assumptions around revenue growth, higher profit margins, and a slightly lower discount rate in their models. Analyst Commentary Bullish analysts have been steadily lifting their price targets on Mirum Pharmaceuticals, pointing to what they see as solid execution, supportive guidance, and a healthy pipeline of potential catalysts.
Narrative Update • May 04

MIRM: Fair Value Views Turn On 2026 PSC Readout

Analysts have lifted the average price target for Mirum Pharmaceuticals from $106.60 to about $129.73, reflecting updated assumptions on revenue growth, margins and future P/E multiples. Analyst Commentary Recent Street research has been active on Mirum Pharmaceuticals, with several firms revisiting their models and resetting price targets.
Narrative Update • Apr 19

MIRM: 2026 PSC Readout Will Reframe Long Term Earnings Power

Analysts recently lifted Mirum Pharmaceuticals' average price target by several dollars to a range of about $117 to $130, citing updated models that reflect slightly higher revenue growth and profit margin assumptions, along with a modestly higher discount rate and continued focus on upcoming clinical and commercial catalysts. Analyst Commentary Bullish analysts have been steadily lifting their valuation work on Mirum Pharmaceuticals, pushing price targets into a band that runs roughly from the high $110s to about $130.
Narrative Update • Apr 05

MIRM: 2026 PSC Readout And Guidance Will Reset Earnings Power Narrative

Analysts have lifted their average price targets on Mirum Pharmaceuticals by several dollars into a range that now runs into the low to mid $100s, citing updated models that incorporate higher revenue growth, stronger profit margins and still elevated but slightly lower future P/E assumptions. Analyst Commentary Recent research has leaned clearly positive on Mirum Pharmaceuticals, with several bullish analysts lifting price targets into a clustered range around the low to mid US$100s.
Narrative Update • Mar 22

MIRM: 2026 Clinical Readouts And Guidance Will Reframe Earnings Power Narrative

Analysts have lifted their average price targets on Mirum Pharmaceuticals into a roughly $117 to $130 range, citing in line reported revenue, reiterated guidance, continued commercial traction in Livmarli and the bile acid portfolio, as well as upcoming clinical catalysts as key supports for the updated views. Analyst Commentary Recent Street research on Mirum Pharmaceuticals has leaned positive, with multiple bullish analysts revisiting their models and adjusting price targets in a tight cluster around the low to mid $120s.
Narrative Update • Mar 07

MIRM: 2026 Pipeline Catalysts And Guidance Will Reshape Earnings Power Narrative

Analysts have lifted their aggregate price targets for Mirum Pharmaceuticals by several dollars into a roughly $117 to $130 range, reflecting updated views on revenue potential, margin expectations and future P/E multiples following recent earnings, guidance and pipeline commentary. Analyst Commentary Recent Street research has tilted clearly positive, with a cluster of bullish analysts lifting their targets into the low to mid US$100s after Mirum's latest earnings, guidance and pipeline updates.
Narrative Update • Feb 21

MIRM: Elevated Expectations Will Hinge On Upcoming PSC Trial Outcome

Analysts have lifted their fair value estimate for Mirum Pharmaceuticals to $95.00 from $56.92, citing higher modeled revenue growth, improved profit margin assumptions, and reinforced confidence in Livmarli and the broader bile acid portfolio, following recent price target increases and new Outperform initiations across the Street. Analyst Commentary Recent Street research around Mirum Pharmaceuticals has centered on the commercial trajectory for Livmarli, the broader bile acid portfolio, and upcoming clinical milestones.
Narrative Update • Feb 07

MIRM: Busy 2026 Pipeline And Guidance Will Reframe Execution Expectations

Narrative Update on Mirum Pharmaceuticals The analyst price target for Mirum Pharmaceuticals has moved from US$89 to US$140. Analysts cite higher modeled fair value, despite adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions following recent price target increases across several research firms.
Analysis Article • Jan 28

Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25%

Despite an already strong run, Mirum Pharmaceuticals, Inc. ( NASDAQ:MIRM ) shares have been powering on, with a gain of...
Narrative Update • Jan 23

MIRM: Fair Value Tied To 2026 PSC Data And Execution Risks

Analysts have nudged their fair value estimate for Mirum Pharmaceuticals higher from $103.10 to $106.60, citing recently raised Street price targets that reflect stronger than expected preliminary results, updated guidance, and continued confidence around Livmarli and the late stage pipeline. Analyst Commentary Street research on Mirum Pharmaceuticals has centered on the recent preliminary results, guidance, and the outlook for Livmarli and the late stage pipeline, with several firms updating their models and fair value assumptions.
Narrative Update • Jan 08

MIRM: Shares Should Benefit From 2026 PSC Volixibat Data Trigger

Narrative Update The analyst price target for Mirum Pharmaceuticals has been raised to $95, up from $81. Analysts point to Livmarli's recent sales performance and upcoming late stage volixibat readouts in primary sclerosing cholangitis and primary biliary cholangitis as key drivers of their updated views.
Narrative Update • Dec 25

MIRM: Shares Should Climb On 2026 PSC Volixibat Pivotal Readout

Analysts have raised their price target on Mirum Pharmaceuticals to $103.10 from $95.20, citing Livmarli's sustained commercial traction and the potential for volixibat's late stage data to drive the next phase of growth toward profitability. Analyst Commentary Recent research updates reflect a generally constructive stance on Mirum Pharmaceuticals, with price targets moving higher as Livmarli execution remains solid and expectations build around the volixibat pipeline.
Narrative Update • Dec 11

MIRM: Shares Will Rise On 2026 Pivotal PSC Volixibat Readout

Mirum Pharmaceuticals' analyst price target has been lifted from $87.99 to $95.20 as analysts highlight Livmarli's strong commercial trajectory, an improving path to profitability, and the potential next wave of growth from late stage volixibat data expected in 2026. Analyst Commentary Bullish analysts see the latest price target increases as a reflection of Mirum's strengthening commercial execution and expanding pipeline visibility.
Narrative Update • Nov 27

MIRM: Shares Will Surge On Pivotal Late-Stage Data Readout In 2026

Mirum Pharmaceuticals' analyst price target has increased from $86.09 to $87.99. This reflects analysts' optimism about continued strong sales, upcoming clinical milestones, and anticipated profitability improvements.
Narrative Update • Nov 13

MIRM: Shares Will Rally On Pivotal Clinical Data Expected In 2026

Analysts have raised their price target for Mirum Pharmaceuticals from $83.55 to $86.09 per share, citing continued strong performance for Livmarli and optimism around late-stage clinical catalysts expected over the next two years. Analyst Commentary Recent research updates reflect a broadly positive outlook for Mirum Pharmaceuticals, with several analysts raising their price targets and emphasizing key growth drivers for the company.
Narrative Update • Oct 30

Upcoming Clinical Milestones Will Drive Rare Disease Pipeline Expansion Into 2026

Mirum Pharmaceuticals' analyst price target has been raised, with the fair value estimate increasing slightly to $83.55 from $83. Analysts cite continued strong Livmarli performance and upcoming clinical milestones as key factors supporting this upward revision.
Analysis Article • Oct 16

Mirum Pharmaceuticals (NASDAQ:MIRM) Is Carrying A Fair Bit Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Narrative Update • Oct 15

Genetic Testing And International Expansion Will Broaden Rare Disease Markets

Analysts have raised their fair value price target for Mirum Pharmaceuticals from $81 to $83, citing higher revenue growth forecasts and strong performance in recent quarters. Analyst Commentary Analysts have expressed a largely positive view on Mirum Pharmaceuticals' outlook, citing several drivers of growth and ongoing execution.
Narrative Update • Sep 25

Genetic Testing And International Expansion Will Broaden Rare Disease Markets

Analysts raised Mirum Pharmaceuticals’ price target from $78.27 to $81.00, citing surging Livmarli sales, strong Q2 results, a robust and expanding rare disease pipeline, and continued commercial execution. Analyst Commentary Bullish analysts meaningfully increased Livmarli sales forecasts following Mirum's strong Q2 earnings beat and upwardly revised 2025 guidance.
Narrative Update • Aug 08

Genetic Testing And International Expansion Will Broaden Rare Disease Markets

Mirum Pharmaceuticals’ modest target price increase reflects improved consensus revenue growth forecasts, though this is partially offset by a slight expansion in the future P/E multiple, resulting in a marginal upward revision of the fair value to $77.20. What's in the News Mirum Pharmaceuticals raised its 2025 revenue guidance to $490 million to $510 million.
User avatar
New Narrative • May 09

FDA And Japanese Approvals Will Open New Markets

Strong revenue growth and recent regulatory approvals are set to expand market reach and positively impact future revenues.
Seeking Alpha • Mar 24

Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like

Summary Mirum Pharmaceuticals, Inc.'s stock has risen over 50% in the past year, despite a recent 15% dip due to market volatility. The company reported strong Q4 results in late February with a 43% Y/Y revenue increase, driven by Livmarli's sales growth. Analysts unanimously rate Mirum as a Buy and expect significant revenue growth and reduced losses.  The company should be cash flow positive by the end of this fiscal year. Mirum's pipeline includes promising candidates like Volixibat and MRM-3379, both with billion-dollar potential, supporting a positive long-term outlook. An updated analysis around MIRM stock follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)

Summary The biotech industry is primed for increased M&A activity due to low valuations and big pharma's need to offset patent losses. Mirum Pharmaceuticals, with three approved drugs and a strong pipeline, is a possible prime takeover candidate with significant growth potential. MIRM's stock shows strong upward momentum, supported by impressive sales growth, positive cash flow, and a clear path to profitability. Wall Street is bullish on MIRM, projecting a 50% upside to $63. We are slightly (a lot) more bullish right now at $64.40 (two years from now at $82.40). Read the full article on Seeking Alpha
Seeking Alpha • Dec 25

Mirum Pharma: Buy At Dips For Volixibat Potential

Summary Mirum Pharma has three approved products and a promising pipeline, with volixibat showing superior interim data for PBC compared to competitors. It is a buy for volixibat's potential, which is 2-3 years away from approval, but supported in the interim by the other approved drugs. Financially, Mirum has a market cap of $2bn, a cash balance of $294mn, and a cash runway of over 12-15 quarters. The key risk lies in the intense competition in the PBC space and the wait for volixibat's approval. Despite trading at the higher end of its 52-week range, Mirum is an attractive buy on dips. Read the full article on Seeking Alpha
Seeking Alpha • Oct 04

Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish

Summary Mirum Pharmaceuticals, Inc.'s stock has risen >150% since 2021, driven by its rare disease treatments, but its current valuation may be overstated given ongoing losses and competitive pressures. The company's key revenue drivers include Livmarli, Cholbam, and Chenodal, with potential peak revenues of around $450M, but profitability remains elusive. Volixibat shows promise in Phase 2b trials for PSC and PBC, but approval is unlikely before 2027, and competition is intense. Mirum's cash burn and lengthy approval timelines suggest a potential downward price correction, with a lower valuation likely in 2025. Read the full article on Seeking Alpha
Seeking Alpha • Jul 17

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Summary Mirum Pharmaceuticals develops therapies for rare liver diseases, focusing on bile acid regulation. Key products include Livmarli, Cholbam, and Chenodal, with Chenodal recently completing Phase 3 trials for CTX. MIRM's pipeline also has Volixibat in Phase 2b trials for PSC and PBC. MIRM's recent acquisition of Cholbam and Chenodal from Travere Therapeutics is strategically significant. I believe that despite trading at a premium, MIRM's growth prospects and strong fundamentals justify a "buy" rating. Read the full article on Seeking Alpha
Seeking Alpha • Apr 22

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Summary The FDA approved Mirum Pharmaceuticals, Inc.'s Limvarli for treatment of cholestatic pruritus in patients with Progressive Familial Intrahepatic Cholestasis; Potential for further label expansion in younger patients possible due to positive MARCH study. Interim results from VANTAGE study using Volixibat for patients with PBC are expected 1st half of 2024; The global primary biliary cholangitis therapeutics market is projected to reach $1.4 billion by 2032. Interim results from VISTAS study using Volixibat for patients with PSC expected 1st half 2024; The global Primary Sclerosing Cholangitis market is expected to reach $586.8 million by 2034. Total net product revenues of $178.9 million for the full-year ending December 2023, compared to the prior year ending December 2022 with net product revenues of only $75.1 million in sales. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Chris Peetz's remuneration changed compared to Mirum Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$860m

Mar 31 2026n/an/a

-US$799m

Dec 31 2025US$10mUS$755k

-US$23m

Sep 30 2025n/an/a

-US$41m

Jun 30 2025n/an/a

-US$59m

Mar 31 2025n/an/a

-US$77m

Dec 31 2024US$7mUS$730k

-US$88m

Sep 30 2024n/an/a

-US$100m

Jun 30 2024n/an/a

-US$109m

Mar 31 2024n/an/a

-US$159m

Dec 31 2023US$6mUS$660k

-US$163m

Sep 30 2023n/an/a

-US$164m

Jun 30 2023n/an/a

-US$176m

Mar 31 2023n/an/a

-US$129m

Dec 31 2022US$4mUS$624k

-US$136m

Sep 30 2022n/an/a

-US$42m

Jun 30 2022n/an/a

-US$53m

Mar 31 2022n/an/a

-US$70m

Dec 31 2021US$4mUS$600k

-US$84m

Sep 30 2021n/an/a

-US$179m

Jun 30 2021n/an/a

-US$153m

Mar 31 2021n/an/a

-US$132m

Dec 31 2020US$3mUS$512k

-US$103m

Sep 30 2020n/an/a

-US$84m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$6mUS$458k

-US$53m

Compensation vs Market: Chris's total compensation ($USD10.44M) is about average for companies of similar size in the US market ($USD8.46M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Peetz (47 yo)

7.5yrs
Tenure
US$10,441,224
Compensation

Mr. Christopher Peetz, also known as Chris, is Independent Director of Arcutis Biotherapeutics, Inc. from July 15, 2026. Mr. Peetz was Independent Director of Alpine Immune Sciences, Inc. from April 24, 20...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Peetz
CEO & Director7.5yrsUS$10.44m0.59%
$ 38.4m
Peter Radovich
COO & President6.4yrsUS$3.96m0.088%
$ 5.8m
Eric Bjerkholt
Chief Financial Officer3yrsUS$3.25m0.056%
$ 3.7m
Jean-Luc Girardet
Chief Technical Officerno datano datano data
Andrew McKibben
Senior Vice Presidentno datano datano data
Douglas Sheehy
Chief Legal Officer & Secretary1.3yrsno datano data
Meredith Kiernan
Senior Director of Global Corporate Communicationsno datano datano data
Erin Campany
Chief People Officer7.7yrsno datano data
Lara Longpre
Chief Development Officer7.8yrsUS$1.51mno data
Vinita Kumar
Senior Vice President of Quality4.7yrsno datano data
Nancy Shulman
Executive Vice President of Clinicalless than a yearno datano data
Hassan Javanbakht
Chief Scientific Officerless than a yearno datano data
4.7yrs
Average Tenure
57yo
Average Age

Experienced Management: MIRM's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Peetz
CEO & Director7.7yrsUS$10.44m0.59%
$ 38.4m
Patrick Heron
Independent Director7.8yrsUS$409.84k0.0088%
$ 573.6k
Laura Brege
Independent Director7.2yrsUS$440.47k0.024%
$ 1.6m
Michael Grey
Independent Non-Executive Chairman of the Board7.5yrsUS$459.84k0.43%
$ 28.2m
Laurent Fischer
Independent Director7.3yrsUS$429.84k0.017%
$ 1.1m
Timothy Walbert
Independent Director3.4yrsUS$414.84k0.015%
$ 974.0k
Sona Saira Ramasastry
Independent Director4.3yrsUS$421.72kno data
William Fairey
Independent Director5.1yrsUS$421.72k0.0039%
$ 251.5k
Lon Cardon
Independent Director3.8yrsUS$404.84k0.015%
$ 974.0k
7.2yrs
Average Tenure
60yo
Average Age

Experienced Board: MIRM's board of directors are considered experienced (7.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 01:13
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mirum Pharmaceuticals, Inc. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Joshua SchimmerCantor Fitzgerald & Co.
Yigal NochomovitzCitigroup Inc